Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide

Cancer Investigation

Volumn 6, Issue 3, 1988, Pages 337-349

  Berd, David ^a   Mastrangelo, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYCLOPHOSPHAMIDE; VACCINE;

CANCER IMMUNOTHERAPY; HUMAN; MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CASE REPORT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNIZATION, PASSIVE; MALE; MELANOMA; MIDDLE AGE; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023785002     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357908809080657     Document Type: Article

References (32)

1. Cancer immunology: the search for specificity
2. Specific immune-reactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly-derived human cells
3. Current condition and prognosis of tumor immunotherapy: A second opinion
4. T cell control of antibody production
5. In Vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice
6. Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis
7. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors
8. Regulation of the immune response to tumor antigens I. Immunosuppressor cells in tumor-bearing hosts
9. Multiple cancers
10. T-cell-mediated suppression of anti-tumor immunity
11. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
12. The influence of cyclophosphamide upon neoplastic diseases in man
13. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lty-1 +,2- lymphocytes
14. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
15. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide
16. Cellular interactions modulating host resistance to tumours
17. Antigen-specific therapy of experimental metastases
18. Tumor bearer T cells suppress BCG-potentiated antitumor responses JJ. Characteristics of the efferent phase suppressor
19. The serologic response to meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants
20. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig
21. Effect of cyclophosphamide on immunological control mechanisms
22. Augmentation of the human immune response by cyclophosphamide
23. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide
24. Impairment of con-canavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer
25. Effect of low dose cyclophosphamide on the immune system of cancer patient. Reduction of T suppressor function without depletion of the CD8+ subset
26. Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4 +, 2H4+ suppressor-inducer T cells
27. The role of the 2H4 molecule in the generation of suppressor function in Con A-activated T cells
28. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide
29. Preparation of immunother-apeutic autologous tumor cell vaccines from solid tumors
30. Antigenic properties of chemically induced tumors
31. Sarcoma induction in mice by methylcholanthrene. Antigenicity tests of sarcomas induced in thymus grafted and control animals
32. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma